[1]赵舸争,夏 凡,方心悦,等.创新药和创新医疗技术临床使用的影响因素：系统综述[J].卫生经济研究,2026,43(01):8-13.
　ZHAO Gezhen,XIA Fan,FANG Xinyue,et al.Systematic Review on the Factors Influencing the Clinical Application of Innovative Drugs and Medical Technologies[J].Journal Press of Health Economics Research,2026,43(01):8-13.
点击复制

创新药和创新医疗技术临床使用的影响因素：系统综述

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年01期
页码:
8-13
栏目:
药械管理
出版日期:
2026-01-06

文章信息/Info

Title:
Systematic Review on the Factors Influencing the Clinical Application of Innovative Drugs and Medical Technologies
作者:
赵舸争1; 夏 凡1; 方心悦1; 金春林2; 甘芳奇3; 邱 月3
1.清华大学深圳国际研究生院，广东 深圳 518071
2.上海市卫生和健康发展研究中心，上海 201100
3.清华大学医疗管理学院，北京 100084
Author(s):
ZHAO Gezhen;  XIA Fan;  FANG Xinyue;  JIN Chunlin;  GAN Fangqi;  QIU Yue
Tsinghua Shenzhen International Graduate School, Shenzhen Guangdong 518071, China
关键词:
创新药; 创新医疗技术; 临床使用; 影响因素
Keywords:
innovative drugs;  innovative medical technologies;  clinical application;  influencing factors
分类号:
R19
文献标志码:
A
摘要:
目的：系统梳理影响创新药和创新医疗技术临床使用的关键因素。方法：检索Pubmed等7个英文数据库和中国知网等3个中文数据库，分类整理影响创新药技使用的关键因素。结果：纳入50篇高质量文献，识别出患者、医生、药品与技术、组织、外部环境5个维度，49个影响因素，其中，疗效、医生知识水平、医疗机构支持、药技费用及医保政策是影响创新药技临床使用的关键因素。结论：创新药技的使用受多种因素影响，应构建以疗效为导向的创新药技使用保障机制，加强医疗机构服务能力建设，完善医疗保险支付体系，推动创新药技临床使用。
Abstract:
Objective To systematically identify the facilitators and barriers influencing the clinical application of innovative drugs and medical technologies. Methods A comprehensive literature search was conducted across seven English databases and three Chinese databases. Key factors influencing the clinical application of innovative drugs and medical technologies were extracted and categorized. Results A total of 50 high-quality studies were included, from which 49 factors were identified. These were grouped into five categories of patient-related factors, physician-related factors, drug-related factors, organizational factors, and external environmental factors. Among these, drug efficacy, physicians' knowledge, institutional support, drug and technology costs, and reimbursement policies emerged as the most critical determinants. Conclusion The clinical application of innovative drugs and medical technologies is influenced by multifaceted factors. It is necessary to establish a therapeutic efficacy-oriented mechanism to ensure the clinical application of innovative drugs and medical technologies, strengthen physician training, enhance institutional capacity, optimize reimbursement mechanisms, and refining policy incentives, so as to promote broader and more effective clinical application.

参考文献/References:

[1] Dutta N, Dhar D J. Understanding medical technology innovation in low-and middle-income countries: factors, impact, and a model proposal[J]. She Ji: The Journal of Design, Economics, and Innovation, 2024, 10(02): 192-222.
[2] Ghodeswar B, Vaidyanathan J J. Adoption of medical technology by hospitals: a review of innovation attributes and a conceptual model of the resulting service[J]. World Review of Science, Technology and Sustainable Development, 2006, 3(04): 362-380.
[3] Chauhan D, Mason A J. Factors affecting the uptake of new medicines in secondary care-a literature review[J]. Journal of Clinical Pharmacy and Therapeutics, 2008, 33(04): 339-348.
[4] 万子瑾.公立医院临床医师抗肿瘤创新药物处方行为的影响机制研究[D].武汉：华中科技大学，2023.
[5] Lublóy á J. Factors affecting the uptake of new medicines: a systematic literature review[J]. BMC Health Services Research, 2014, 14(01): 469.
[6] Akenroye T O. Factors influencing innovation in healthcare: a conceptual synthesis[J]. The Innovation Journal, 2012, 17(02): 1.
[7] 官海静，陶立波，韩晟.创新药价格形成与医保准入的影响因素分析[J].中国医疗保险，2024（06）：15-20.
[8] 董江萍.第三方对美国创新药首轮审评通过率影响因素评估的介绍[J].中国医药工业杂志，2009，40（01）：71-75.
[9] 张星.江苏创新药入院使用问题调查与改革举措[J].唯实，2024（11）：46-48.
[10] Chaudoir S R, Dugan A G, Barr C H. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures[J]. Implementation Science, 2013, 8(01): 22.
[11] Petrosyan Y, Simmons J G, Kelly E, et al. Uptake and factors associated with direct-acting antiviral therapy for hepatitis C and treatment outcomes among Canadian immigrants: a retrospective cohort analysis[J]. Can Liver J, 2022, 5(03): 388-401.
[12] Donohue J M, Guclu H, Gellad W F, et al. Influence of peer networks on physician adoption of new drugs[J]. PloS one, 2018, 13(10): e0204826.
[13] Chen H L, Shen L J, Wei C P, et al. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients[J]. Journal of Evaluation in Clinical Practice, 2015, 21(05): 808-816.
[14] Gao X Y, Yu M, Sun Y Y, et al. New evidence of the impact of the national drug price negotiation policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: an interrupted time series study[J]. Risk Manag Healthc Policy, 2024, 17: 2201-2208.
[15] Diao Y, Lin M, Xu K, et al. Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design[J]. BMJ Open, 2022, 12(02): e054713.
[16] Qureshi N, Huilgol S S, Berdahl C T, et al. Understanding uptake of information about innovations among emergency department clinicians during the COVID-19 pandemic[J]. Journal of the American College of Emergency Physicians open, 2024, 5(04): e13243.
[17] Wang X, Wu Q, Lian Z, et al. Factors associated with the adoption of targeted therapy for human epidermal growth factor receptor 2(HER 2) positive breast cancer[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(01): 7-13.
[18] Edib Z, Jayasinghe Y, Hickey M, et al. Exploring the facilitators and barriers to using an online infertility risk prediction tool (FoRECAsT) for young women with breast cancer: a qualitative study protocol[J]. BMJ Open, 2020, 10(02): e033669.
[19] Nguyen C Q, Kariyawasam D S, Ngai T S, et al. High hopes for treatment: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases[J]. Health Expectations, 2024, 27(03): e14063.
[20] Ghariq M, Van Bodegom-Vos L, Brignole M, et al. Factors facilitating and hindering the implementation of the European Society of Cardiology Syncope Guidelines at the Emergency Department: a nationwide qualitative study[J]. Int J Cardiol, 2021, 333: 167-173.
[21] Dev S, Hoffman T K, Kavalieratos D, et al. Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study[J]. Journal of the American Heart Association, 2016, 5(03): e002493.
[22] Spinnewijn L, Aarts J W, Braat D, et al. Unravelling clinicians' shared decision-making adoption: a qualitative exploration through the lens of diffusion of innovations theory[J]. BMJ Open, 2024, 14(06): e080765.
[23] Thijssen S V, Boersma L J, Heising L, et al. Clues to address barriers for access to proton therapy in the Netherlands[J]. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 2023, 178: 109432.
[24] Medlinskiene K, Richardson S, Petty D, et al. Barriers and enablers to healthcare system uptake of direct oral anticoagulants for stroke prevention in atrial fibrillation: a qualitative interview study with healthcare professionals and policy makers in England[J]. BMJ Open, 2023, 13(04): e069575.
[25] Hernandez J, Machacz S F, Robinson J C. US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan[J]. Health affairs (Project Hope), 2015, 34(02): 261-270.
[26] YuTong T, Yan Z, Zhen L, et al. Telehealth readiness and its influencing factors among chinese clinical nurses: a cross-sectional study[J]. Nurse Education in Practice, 2022, 58: 103278.
[27] Ollila E, Kataja V, Sailas L. A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland[J]. Journal of Pharmaceutical Policy and Practice, 2022, 15(01): 52.
[28] Nair M, Andersson J, Nygren J M, et al. Barriers and enablers for implementation of an artificial intelligence-based decision support tool to reduce the risk of readmission of patients with heart failure: stakeholder interviews[J]. JMIR Formative Research, 2023, 7: e47335.
[29] Matlala M, Gous A G, Meyer J C, et al. Formulary management activities and practice implications among public sector hospital pharmaceutical and therapeutics committees in a South African Province[J]. Frontiers in Pharmacology, 2020, 11: 1267.
[30] Bostwick L W, Champion J D. Translation of novel antiemetic to sub‐Saharan Africa using diffusion of innovation framework[J]. Public Health Nursing, 2022, 39(03): 528-535.
[31] Tachi T, Saito K, Esaki H, et al. Medical and economic factors influencing generic drug use in the Japanese public health system: influencing factors in different populations[J]. The International Journal of Health Planning and Management, 2018, 33(02): 489-501.
[32] Razvi Y, Horwitz S L, Cressman C, et al. Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: a qualitative institutional case study[J]. PloS One, 2024, 19(03): e0300519.
[33] Roberts N, Hooper G, Lorencatto F, et al. Barriers and facilitators towards implementing the Sepsis Six care bundle(BLISS-1): a mixed methods investigation using the theoretical domains framework[J]. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2017, 25(01): 96.
[34] Sundaresan P, King M T, Stockler M R, et al. Barriers to radiotherapy utilisation in New South Wales Australia: health professionals' perceptions of impacting factors[J]. Journal of Medical Imaging and Radiation Oncology, 2015, 59(04): 535-541.
[35] Infante K, Madhavan P, Stojanovic I, et al. Pbi33 can innovative payment reform be the solution to address reimbursement and uptake challenges for car-t therapies?[J]. Value in Health, 2019, 22: S53.
[36] Gilstrap L, King A, Tomlin S, et al. Variation in early diffusion of sacubitril/valsartan and implications for understanding novel drug diffusion[J]. The American Journal of Managed Care, 2021, 27(12): 524-530.
[37] Aziz Z, Naseer H, Altaf A. Challenges in access to new therapeutic agents: marginalized patients with cancer in pakistan and the need for new guidelines[J]. JCO Global Oncology, 2022, 8: e2100132.
[38] Reyes-Santias F, Antelo M. Explaining the adoption and use of computed tomography and magnetic resonance image technologies in public hospitals[J]. BMC Health Services Research, 2021, 21(01): 1278.
[39] Warmbein A, Rathgeber I, Seif J, et al. Barriers and facilitators in the implementation of mobilization robots in hospitals from the perspective of clinical experts and developers[J]. BMC Nursing, 2023, 22(01): 45.
[40] Scholten N, Pfaff H, Lehmann H C, et al. Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data[J]. Implementation Science: IS, 2015, 10: 10.
[41] Lauren G, King A, Tomlin S, et al. Variation in early diffusion of sacubitril/ Valsartan and implications for understanding novel drug diffusion[J]. American Journal of Managed Care, 2021, 27(12): 524-530.
[42] Pannier A. Long-Chain Fatty Acid Oxidation Disorders: Managed Care and Specialty Pharmacy Implications[J]. American Journal of Managed Care, 2020, 26: S155-S161.
[43] Maleki M, Mousavi S M, Khosravizadeh O, et al. Factors affecting use of telemedicine and telesurgery in cancer care(TTCC) among Specialist Physicians[J]. Asian Pacific Journal of Cancer Prevention: APJCP, 2018, 19(11): 3123-3129.
[44] Abedini Z, Sari A A, Foroushani A R, et al. Diffusion of advanced medical imaging technology, CT, and MRI scanners, in Iran: a qualitative study of determinants[J]. Int J Health Plan Manag, 2019, 34(01): E397-E410.
[45] Fang W, Xu X, Zhu Y, et al. Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: an Interrupted Time-Series Study[J]. Frontiers i n Public Health, 2021, 9: 714127.
[46] Keating N L, O'Malley A J, Onnela J P, et al. Association of physician peer influence with subsequent physician adoption and use of bevacizumab[J]. JAMA Network Open, 2020, 3(01): e1918586.
[47] Saka A K, Ferenbok J. Improving the uptake of transcatheter aortic valve replacement in ontario[J]. Cureus, 2021, 13(07): e16364.
[48] Vancelik S, Beyhun N E, Acemoglu H, et al. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey[J]. BMC Public Health, 2007, 7: 122.
[49] 于飞，卢静，高辰旭，等.中外创新药物医保支付的比较研究[J].医药导报，2024，43（03）：470-476.

相似文献/References:

[1]丛鹂萱,王海银,金春林.美国创新医疗技术支付经验及启示[J].卫生经济研究,2019,(07):10.
　CONG Li-xuan,WANG Hai-yin,JIN Chun-lin.American Innovative Medical Technology Payment Experience and Enlightenment[J].Journal Press of Health Economics Research,2019,(01):10.
[2]付瑞枫,茅宁莹.“双通道”背景下国谈创新药零售终端流通现状[J].卫生经济研究,2023,40(2):24.
　FU Ruifeng,MAO Ningying.Analysis on the Circulation and Obstacles of Innovative Drugs in Retail Terminal under the Dual-channel Policy in China[J].Journal Press of Health Economics Research,2023,40(01):24.
[3]陈非非,张璐莹,俞纯璐,等.DRG付费下创新医疗技术的额外支付机制研究 ——基于国际经验与启示[J].卫生经济研究,2023,40(8):28.
　CHEN Feifei,ZHANG Luying,YU Chunlu,et al.Study on Additional Payment Mechanism for Innovative Medical Technologies under DRG Payment ——Based on International Experience and Enlightenment[J].Journal Press of Health Economics Research,2023,40(01):28.
[4]谭清立,李永盈,崔洪瑞.创新药医保谈判的博弈分析[J].卫生经济研究,2024,41(06):5.
　TAN Qingli,LI Yongying,CUI Hongrui.Game Analysis of Health Insurance Negotiation for Innovative Drug[J].Journal Press of Health Economics Research,2024,41(01):5.
[5]王佳玮sup>,徐俊芳.外部参考定价在我国创新药医保准入中的应用研究[J].卫生经济研究,2025,42(09):29.
　WANG Jiawei,XU Junfang.Research on the Application of External Reference Pricing in Innovative Drug Medical Insurance Access in China[J].Journal Press of Health Economics Research,2025,42(01):29.

更新日期/Last Update: 2026-01-06